{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:52:21Z","timestamp":1778543541357,"version":"3.51.4"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Although the survival rate of patients with multiple myeloma has significantly improved in the last years thanks to the introduction of various classes of new drugs, such as proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies, the vast majority of these subjects relapse with a more aggressive disease due to the acquisition of further genetic alterations that may cause resistance to current salvage therapies. The treatment of these often \u201ctriple\u201d (or even more) refractory patients remains challenging, and alternative approaches are required to overcome the onset of that resistance. Immunotherapies with novel monoclonal, drug-conjugated, or bi-specific antibodies, as well as the use of chimeric antigen receptor T cells, have been recently developed and are currently investigated. However, other non-immunologic therapeutic regimens based on melfluflen, venetoclax, or selinexor, three molecules with new mechanisms of action, have also shown promising results in the setting of relapsed\/refractory myeloma. Here we report the most recent literature data regarding these three drugs, focusing on their efficacy and safety in multiple myeloma.<\/jats:p>","DOI":"10.3389\/fonc.2021.716751","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T17:40:59Z","timestamp":1633023659000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor"],"prefix":"10.3389","volume":"11","author":[{"given":"Nicola","family":"Sgherza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Curci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","article-title":"The Impact of Disease-Related Symptoms and Palliative Care Concerns on Health-Related Quality of Life in Multiple Myeloma: A Multi-Centre Study","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138","article-title":"Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of Patients With Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody Therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12805","article-title":"The Impact of Intra-Clonal Heterogeneity on the Treatment of Multiple Myeloma","volume":"165","author":"Brioli","year":"2014","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal Competition With Alternating Dominance in Multiple Myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple Myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of Relapsed and Refractory Multiple Myeloma: Recommendations From the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ph14010040","article-title":"Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies Off the Shelf","volume":"14","author":"Baril\u00e0","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T Cell Therapies for Patients With Multiple Myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3752","article-title":"In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, Against Multiple Myeloma Cells","volume":"19","author":"Chauhan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18420","article-title":"Melflufen - A Peptidase-Potentiated Alkylating Agent in Clinical Trials","volume":"8","author":"Wickstr\u00f6m","year":"2017","journal-title":"Oncotarget"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.12.022","article-title":"The Alkylating Prodrug J1 Can Be Activated by Aminopeptidase N, Leading to a Possible Target Directed Release of Melphalan","volume":"79","author":"Wickstr\u00f6m","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/10611860310001647140","article-title":"Activity of Hydrolytic Enzymes in Tumour Cells Is a Determinant for Anti-Tumour Efficacy of the Melphalan Containing Prodrug J1","volume":"11","author":"Gullbo","year":"2003","journal-title":"J Drug Target"},{"key":"B15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/bjh.14065","article-title":"A Novel Alkylating Agent Melflufen Induces Irreversible DNA Damage and Cytotoxicity in Multiple Myeloma Cells","volume":"174","author":"Ray","year":"2016","journal-title":"Br J Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-1843","article-title":"Melflufen Efficacy in Multiple Myeloma With TP53 Aberrations","volume":"80","author":"Slipicevic","year":"2020","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103120","article-title":"Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma","volume":"9","author":"Mateos","year":"2020","journal-title":"J Clin Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30044-2","article-title":"Melflufen Plus Dexamethasone in Relapsed and Refractory Multiple Myeloma (O-12-M1): A Multicentre, International, Open-Label, Phase 1-2 Study","volume":"7","author":"Richardson","year":"2020","journal-title":"Lancet Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02259","article-title":"Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2020-13599","article-title":"ANCHOR (OP-104): Melflufen Plus Dexamethasone (Dex) and Daratumumab (Dara) or Bortezomib (BTZ) in Relapsed\/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and\/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety","volume":"136","author":"Ocio","year":"2020","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"abstr 8037","DOI":"10.1200\/JCO.2021.39.15_suppl.8037","article-title":"ANCHOR (OP-104): Melflufen Plus Dexamethasone (Dex) and Bortezomib (BTZ) in Relapsed\/Refractory Multiple Myeloma (RRMM)\u2014Optimal Dose, Updated Efficacy and Safety Results","volume":"39","author":"Hajek","year":"2021","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0024","article-title":"OCEAN: A Randomized Phase III Study of Melflufen + Dexamethasone to Treat Relapsed Refractory Multiple Myeloma","volume":"16","author":"Schjesvold","year":"2020","journal-title":"Future Oncol"},{"key":"B23","first-page":"488","article-title":"BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients With Relapsed\/Refractory Multiple Myeloma and Impaired Renal Function","volume-title":"EHA2021 Virtual Congress Abstract Book","author":"Pour","year":"2021"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17302","article-title":"Melflufen Plus Dexamethasone in Relapsed\/Refractory Multiple Myeloma: Long-Term Survival Follow-Up From the Phase II Study O-12-M1","volume":"193","author":"Bringhen","year":"2021","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100643","article-title":"The Evolving Role of Translocation T(11;14) in the Biology, Prognosis, and Management of Multiple Myeloma","volume":"41","author":"Paner","year":"2020","journal-title":"Blood Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients With Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discovery"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.254.254","article-title":"A Phase 1 Study of Venetoclax (ABT-199 \/ GDC-0199) Monotherapy in Patients With Relapsed\/Refractory Non-Hodgkin Lymphoma","volume":"126","author":"Gerecitano","year":"2015","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 With Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukaemia With 17p Deletion: A Multicentre, Open-Label, Phase 2 Study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-704908","article-title":"Hierarchy for Targeting Prosurvival BCL2 Family Proteins in Multiple Myeloma: Pivotal Role of MCL1","volume":"128","author":"Gong","year":"2016","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163","article-title":"Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.350","article-title":"Dexamethasone Treatment Promotes Bcl-2 Dependence in Multiple Myeloma Resulting in Sensitivity to Venetoclax","volume":"30","author":"Matulis","year":"2016","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of Venetoclax as Targeted Therapy for Relapsed\/Refractory T(11;14) Multiple Myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26083","article-title":"Targeting BCL-2 With Venetoclax and Dexamethasone in Patients With Relapsed\/Refractory T(11;14) Multiple Myeloma","volume":"96","author":"Kaufman","year":"2021","journal-title":"Am J Hematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising Efficacy and Acceptable Safety of Venetoclax Plus Bortezomib and Dexamethasone in Relapsed\/Refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or Placebo in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (BELLINI): A Randomised, Double-Blind, Multicentre, Phase 3 Trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8509","article-title":"Updated Results From BELLINI, A Phase III Study of Venetoclax or Placebo in Combination With Bortezomib and Dexamethasone in Relapsed\/Refractory Multiple Myeloma","volume":"38","author":"Kumar","year":"2020","journal-title":"JCO"},{"key":"B38","doi-asserted-by":"crossref","first-page":"1, PS1375","DOI":"10.1097\/01.HS9.0000563776.65272.b6","article-title":"Updated Safety and Efficacy From a Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"3","author":"Costa","year":"2019","journal-title":"HemaSphere"},{"key":"B39","doi-asserted-by":"publisher","first-page":"8004","DOI":"10.1200\/JCO.2018.36.15_suppl.8004","article-title":"Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"36","author":"Costa","year":"2018","journal-title":"JCO"},{"key":"B40","first-page":"2319","article-title":"A Phase 3, Randomized, Multicenter, Open-Label Study of Venetoclax or Pomalidomide in Combination With Dexamethasone in Patients With T(11;14)-Positive Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Mateos","year":"2020","journal-title":"Blood"},{"key":"B41","unstructured":"ClinicalTrials.Gov"},{"key":"B42","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1200\/JCO.2020.38.15_suppl.8511","article-title":"Updated Analysis of a Phase I\/II Study of Venetoclax in Combination With Daratumumab and Dexamethasone, +\/- Bortezomib, in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"38","author":"Kaufman","year":"2020","journal-title":"JCO"},{"key":"B43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ajh.26207","article-title":"Safety and Preliminary Efficacy Results From a Phase Ib\/II Study of Cobimetinib As a Single Agent and in Combination With Venetoclax With or Without Atezolizumab in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Schjesvold","year":"2020","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26207","article-title":"Low Dose Venetoclax as a Single Agent Treatment of Plasma Cell Malignancies Harboring T(11;14)","volume":"96","author":"Nahi","year":"2021","journal-title":"Am J Hematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1709835","article-title":"A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed\/Refractory Multiple Myeloma","volume":"61","author":"Kambhampati","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2736","article-title":"Venetoclax Plus Bortezomib and Dexamethasone in Heavily Pretreated End-Stage Myeloma Patients Without T(11;14): A Real-World Cohort","volume":"38","author":"Jelinek","year":"2020","journal-title":"Hematol Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16483","article-title":"Carfilzomib, Venetoclax and Dexamethasone for Relapsed\/Refractory Multiple Myeloma","volume":"189","author":"Boccon-Gibod","year":"2020","journal-title":"Br J Haematol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13256-020-02376-y","article-title":"Venetoclax in Combination With Carfilzomib and Dexamethasone in Relapsed\/Refractory Multiple Myeloma Harboring T(11,14)(Q13;Q32): Two Case Reports and a Review of the Literature","volume":"14","author":"Abuelgasim","year":"2020","journal-title":"J Med Case Rep"},{"key":"B49","article-title":"Efficacy and Safety of Venetoclax Combinations in T(11;14) Multiple Myeloma: Real World Data of 50 Patients Collected From 7 Hungarian Centers","volume-title":"EHA2021 Virtual Congress Abstract Book","author":"Szita","year":"2021"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16454","article-title":"Real-world Data Saf efficacy venetoclax-based regimens relapsed\/refractory t(11;14) multiple myeloma","volume":"189","author":"Basali","year":"2020","journal-title":"Br J Haematol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.05.028","article-title":"Biologic Implications of T(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax","volume":"20","author":"Soleimani","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.160408","article-title":"Deep and Sustained Response After Venetoclax Therapy in a Patient With Very Advanced Refractory Myeloma With Translocation T(11;14)","volume":"102","author":"Touzeau","year":"2017","journal-title":"Haematologica"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16858","article-title":"Secondary Plasma Cell Leukaemia Treated With Single Agent Venetoclax","volume":"190","author":"Glavey","year":"2020","journal-title":"Br J Haematol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25331","article-title":"Single- Agent Venetoclax Induces MRD-Negative Response in Relapsed Primary Plasma Cell Leukemia With T(11;14)","volume":"94","author":"Jelinek","year":"2019","journal-title":"Am J Hematol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.003","article-title":"Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma","volume":"18","author":"Rahbari","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.232330","article-title":"Venetoclax in Combination With Carfilzomib, Doxorubicin and Dexamethasone Restores Responsiveness in an Otherwise Treatment-Refractory Multiple Myeloma Patient","volume":"105","author":"Kovacs","year":"2020","journal-title":"Haematologica"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219895072","article-title":"A Successful Case of Venetoclax-Based Therapy in Relapsed\/Refractory Secondary Plasma Cell Leukemia","volume":"26","author":"Kupsh","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.228338","article-title":"Successful Venetoclax Salvage in the Setting of Refractory, Dialysis-Dependent Multiple Myeloma With T(11;14)","volume":"105","author":"Swan","year":"2020","journal-title":"Haematologica"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25676","article-title":"The Combination of Venetoclax, Daratumumab and Dexamethasone for the Treatment of Refractory Primary Plasma Cell Leukemia","volume":"95","author":"Nalghranyan","year":"2020","journal-title":"Am J Hematol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"8823877","DOI":"10.1155\/2020\/8823877","article-title":"Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia With T(11;14) and TP53 Mutation: A Case Report and Literature Review","author":"Valliani","year":"2020","journal-title":"Case Rep Hematol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.172","article-title":"Genome-Wide Studies in Multiple Myeloma Identify XPO1\/CRM1 as a Critical Target Validated Using the Selective Nuclear Export Inhibitor KPT-276","volume":"27","author":"Schmidt","year":"2013","journal-title":"Leukemia"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01188-9","article-title":"Selinexor: First Global Approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-797886","article-title":"Safety and Efficacy of Selinexor in Relapsed or Refractory Multiple Myeloma and Waldenstrom Macroglobulinemia","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/leu.2012.219","article-title":"Antileukemic Activity of Nuclear Export Inhibitors That Spare Normal Hematopoietic Cells","volume":"27","author":"Etchin","year":"2013","journal-title":"Leukemia"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 Inhibition Induces Tumor Cell Cytotoxicity and Impairs Osteoclastogenesis in Multiple Myeloma: Molecular Mechanisms and Therapeutic Implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.08.011","article-title":"Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies","volume":"19","author":"Allegra","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12969","article-title":"XPO1 Inhibitor Combination Therapy With Bortezomib or Carfilzomib Induces Nuclear Localization of I\u03bab\u03b1 and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma","volume":"7","author":"Turner","year":"2016","journal-title":"Oncotarget"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1713088","article-title":"Selective Inhibitors of Nuclear Export (SINEs) in Myeloma: Breakthrough or Bust","volume":"19","author":"Nishihori","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.5207","article-title":"Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma","volume":"36","author":"Vogl","year":"2018","journal-title":"J Clin Oncol"},{"key":"B71","volume-title":"Prescribing Information. Reference ID: 4457635\u2014US FDA","year":""},{"key":"B72","doi-asserted-by":"publisher","first-page":"abstr e20002","DOI":"10.1200\/JCO.2021.39.15_suppl.e20002","article-title":"Results of the Phase 2 MARCH Study: Oral ATG-010 (Selinexor) Plus Low Dose Dexamethasone in Chinese Patients With Relapsed\/Refractory Multiple Myeloma (RRMM) Previously Treated With an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)","volume":"39","author":"Fu","year":"2021","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"abstr 8018","DOI":"10.1200\/JCO.2021.39.15_suppl.8018","article-title":"Oral Selinexor, Pomalidomide, and Dexamethasone (XPd) at Recommended Phase 2 Dose in Relapsed Refractory Multiple Myeloma (MM)","volume":"39","author":"White","year":"2021","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140141","article-title":"Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients With Relapsed\/Refractory and Newly Diagnosed Multiple Myeloma","volume":"136","author":"White","year":"2020","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/jha2.122","article-title":"Selinexor, Daratumumab, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","volume":"2","author":"Gasparetto","year":"2020","journal-title":"eJHaem"},{"key":"B76","doi-asserted-by":"publisher","first-page":"abstr 8038","DOI":"10.1200\/JCO.2021.39.15_suppl.8038","article-title":"Once Weekly Selinexor, Carfilzomib, and Dexamethasone (XKd) in Carfilzomib Nonrefractory Multiple Myeloma (MM) Patients","volume":"39","author":"Gasparetto","year":"2021","journal-title":"J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858852","article-title":"Selinexor Plus Low-Dose Bortezomib and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma","volume":"132","author":"Bahlis","year":"2018","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.clml.2019.12.013","article-title":"Phase I Study of Selinexor, Ixazomib, and Low-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","volume":"20","author":"Salcedo","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15969","article-title":"Phase 1 Study of Selinexor Plus Carfilzomib and Dexamethasone for the Treatment of Relapsed\/Refractory Multiple Myeloma","volume":"186","author":"Jakubowiak","year":"2019","journal-title":"Br J Haematol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.3095.3095","article-title":"Phase I\/II Study of Liposomal Doxorubicin (DOX) in Combination With Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)","volume":"130","author":"Baz","year":"2017","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-Per-Week Selinexor, Bortezomib, and Dexamethasone Versus Twice-Per-Week Bortezomib and Dexamethasone in Patients With Multiple Myeloma (BOSTON): A Randomised, Open-Label, Phase 3 Trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"B82","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.1182\/blood-2019-123672","article-title":"Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients","volume":"134","author":"Brown","year":"2019","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26010","article-title":"Overall Survival of Patients With Triple-Class Refractory Multiple Myeloma Treated With Selinexor Plus Dexamethasone vs Standard of Care in MAMMOTH","volume":"96","author":"Cornell","year":"2021","journal-title":"Am J Hematol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"abstr 8019","DOI":"10.1200\/JCO.2021.39.15_suppl.8019","article-title":"Survival Among Older Patients With Previously Treated Multiple Myeloma Treated With Selinexor, Bortezomib, and Dexamethasone (XVd) in the BOSTON Study","volume":"39","author":"Facon","year":"2021","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"abstr 8024","DOI":"10.1200\/JCO.2021.39.15_suppl.8024","article-title":"Effects of Refractory Status to Lenalidomide on Safety and Efficacy of Selinexor, Bortezomib, and Dexamethasone (XVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Previously Treated Multiple Myeloma","volume":"39","author":"Leleu","year":"2021","journal-title":"J Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04293-y","article-title":"Selinexor, Bortezomib, and Dexamethasone (SVD) in Heavily Treated Relapsed Refractory Multiple Myeloma","author":"Mouhieddine","year":"2020","journal-title":"Ann Hematol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.07.016","article-title":"Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series","volume":"20","author":"Magen","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S227166","article-title":"Clinical Utility of Selinexor\/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection","volume":"13","author":"Malandrakis","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B89","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1182\/blood-2019-131321","article-title":"The Result of a Phase 1 Study of Selinexor in Combination With High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma","volume":"134","author":"Nishihori","year":"2019","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","first-page":"abstr TPS8055","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8055","article-title":"A Randomized, Open-Label, Phase 3 Study of Low-Dose Selinexor and Lenalidomide (Len) Versus Len Maintenance Post Autologous Stem Cell Transplant (ASCT) for Newly Diagnosed Multiple Myeloma (NDMM): ALLG MM23, Sealand","volume":"39","author":"Quach","year":"2021","journal-title":"J Clin Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.3134.3134","article-title":"Eltanexor (KPT-8602), A Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients With Refractory Multiple Myeloma","volume":"130","author":"Cornell","year":"2017","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1808884","article-title":"Melflufen for Relapsed and Refractory Multiple Myeloma","volume":"29","author":"Oriol","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1548931","article-title":"Venetoclax for the Treatment of Multiple Myeloma","volume":"11","author":"Vaxman","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139173","article-title":"Efficacy of Selinexor Based Regimens in Relapsed Refractory Multiple Myeloma: A Systematic Review","volume":"136","author":"Khalid","year":"2020","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0756-6","article-title":"Integrated Safety Profile of Selinexor in Multiple Myeloma: Experience From 437 Patients Enrolled in Clinical Trials","volume":"34","author":"Gavriatopoulou","year":"2020","journal-title":"Leukemia"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27973","article-title":"Developing Next Generation Immunomodulatory Drugs and Their Combinations in Multiple Myeloma","volume":"12","author":"Thakurta","year":"2021","journal-title":"Oncotarget"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.716751\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T17:41:11Z","timestamp":1633023671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.716751\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":96,"alternative-id":["10.3389\/fonc.2021.716751"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.716751","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]},"article-number":"716751"}}